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Abstract
Immune-mediated diseases (IMDs) arise when tolerance is lost and chronic inflammation is targeted towards healthy
tissues. Despite their growing prevalence, therapies to treat IMDs are lacking. Cytokines and their receptors orchestrate
inflammatory responses by regulating elaborate signalling networks across multiple cell types making it challenging to
pinpoint therapeutically relevant drivers of IMDs. We developed an analytical framework that integrates Mendelian
randomization (MR) and multiple-trait colocalization (moloc) analyses to highlight putative cell-specific drivers of IMDs. MR
evaluated causal associations between the levels of 10 circulating cytokines and 9 IMDs within human populations.
Subsequently, we undertook moloc analyses to assess whether IMD trait, cytokine protein and corresponding gene
expression are driven by a shared causal variant. Moreover, we leveraged gene expression data from three separate cell
types (monocytes, neutrophils and T cells) to discern whether associations may be attributed to cell type-specific drivers of
disease. MR analyses supported a causal role for IL-18 in inflammatory bowel disease (IBD) (P =1.17×10−4) and
eczema/dermatitis (P = 2.81×10−3), as well as associations between IL-2rα and IL-6R with several other IMDs. Moloc
strengthened evidence of a causal association for these results, as well as providing evidence of a monocyte and
neutrophil-driven role for IL-18 in IBD pathogenesis. In contrast, IL-2rα and IL-6R associations were found to be T cell
specific. Our analytical pipeline can help to elucidate putative molecular pathways in the pathogeneses of IMDs, which
could be applied to other disease contexts.
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz155/5528728 by U
niversity Library user on 12 Septem
ber 2019
2 Human Molecular Genetics, 2019, Vol. 00, No. 00
Introduction
Autoimmune and atopic diseases may arise due to a lack of
immune tolerance towards self-antigen or harmless allergens,
respectively (1). Loss of immune tolerance results in recurrent
or chronic inflammation, causing damage to healthy tissues
and extensive morbidity. The incidence of immune-mediated
diseases (IMDs) has drastically increased in recent decades,
highlighting the need for a clearer understanding of their
pathogeneses and effective drug discovery (2). Cytokines and
growth factors (herein referred to as cytokines) are signalling
factors that orchestrate the balance between immune home-
ostasis and inflammation via complex signalling pathways (3).
However, traditional observational epidemiological studies are
prone to confounding and reverse causation, making it chal-
lenging to disentangle causal effects of individual cytokines on
IMDs (4).
Genome-wide association studies (GWASs) have been
instrumental in identifying large numbers of genetic loci that
influence disease risk. This includes associations between genes
responsible for the synthesis of cytokines and their receptors
with autoimmune diseases such as inflammatory bowel disease
(IBD) (5–8), multiple sclerosis (MS) (9–11), rheumatoid arthritis
(RA) (12) and systemic lupus erythematosus (13), aswell as atopic
diseases such as eczema (14) and asthma (15). This suggests that
particular inflammatory cytokines may have a causal effect
on the development of these diseases (4). Previous studies
have not yet integrated genome-wide association and cytokine
loci data with cell or tissue-specific gene expression loci
data to characterize the molecular basis of IMD pathogenesis.
Identifying immune cell-specific disease drivers, as well as
putative causal relationships between cytokines and IMDs, will
help to elucidate complex IMDpathways and identify drug target
candidates for therapeutic intervention. Furthermore, targets
supported by evidence from statistical analyses of human
genetic data are thought to have double the success rate in
clinical development (16).
Mendelian randomization (MR) is an increasingly popular
statistical method used to strengthen causal inference with
respect to exposure–disease associations within human popu-
lations, in the absence of confounding variables. MR uses single
nucleotide polymorphisms (SNPs), identified through GWAS, as
unconfounded proxies for an exposure of interest, analogous
to a randomized controlled trial (17). In this study, we have
used a conservative (single SNP) and liberal (multiple SNPs)
two-sample MR analysis to investigate associations between
11 circulating inflammatory biomarkers (cytokines or cytokine
receptors (18–23); Supplementary Material, Table S1) and 9 IMDs
(Supplementary Material, Table S2).
We subsequently applied multiple-trait colocalization
(moloc) (24) to investigate whether associations detected by
MR are due to IMD and circulating cytokine protein sharing a
causal variant. Evidence suggesting that they do can strengthen
findings from MR that variation in cytokine protein levels
has a causal influence on IMD risk. Furthermore, we also
integrated data concerning the gene expression of associated
cytokines derived from three different cell types (monocytes,
neutrophils and T cells) (25). This allowed us to discern whether
associations may be due to genetic drivers that influence
IMD risk via changes in cell type-specific gene expression. As
such, our findings can help develop mechanistic understanding
into the regulatory mechanisms underlying associations from
GWAS.
Results
MR analyses identify putative causal relationships
between circulating cytokine/cytokine receptor levels
and IMDs
We first used a conservative MR approach to detect associations
between inflammatory biomarkers and IMDs, using single
cis-acting SNPs (i.e. within 1 MB distance of their associated
gene) as instruments based on findings from a previous
GWAS that reported genetic associations circulating cytokine
levels (18). Genes assessed were IL-18, IL-2Rα, VEGFA, MIF, IL-
16, HGF, IL-6R, CRP and IL-1R. We were unable to investigate
IP-10 and TRAIL as their cis-acting SNPs had minor allele
frequencies too rare (<0.05) to undertake formal two-sample
MR. Results from the conservative MR analysis are displayed
in Fig. 1 and Supplementary Material, Table S3. Based on a
Bonferroni corrected P-value threshold of P ≤6.17×10−4,
we identified associations between soluble IL-6R levels and
eczema/dermatitis (P =1.35×10−8), RA (P =5.67× 10−8), Crohn’s
disease (P =2.81×10−5) and asthma (P =1.12× 10−4), as well as
an association between IL-2Rα levels and MS (P =1.75× 10−5).
We next performed a liberal MR analysis using all available
instruments (i.e. acting in either cis or trans), associated with our
inflammatory biomarkers (Exposure, Supplementary Material,
Table S1) as instruments. IL-6R (SNPs affecting levels of solu-
ble IL-6R only), MIF and IL-2Rα were excluded from the liberal
analysis as they only had a single cis-acting instrument after
undertaking linkage disequilibrium (LD) clumping of r2 <0.001.
Our Bonferroni corrected P-value threshold for the number of
Liberal MR analyses undertaken was P ≤ 6.14×10−4. There was
strong evidence of association between circulating levels of IL-18
and IBD (P=1.17× 10−4) and eczema/dermatitis (P=2.81× 10−3).
Although these associations were only moderately detected in
the conservative analysis using the IL-18 SNP (rs71478720) alone
(P =1.06×10−2, E/D: P =2.81×10−3), using multiple instruments
in the liberal MR provided stronger evidence of association.
One of the advantages of the liberal MR analysis is that
sensitivity analyses can be performed to test the robustness and
the direction of putative inferred causal relationships. Thus,
we next conducted a leave-one-out analysis to ensure that
no single SNP from the instruments was responsible for the
observed effect. Both the analyses of IL-18 on IBD (Fig. 2) and on
eczema/dermatitis (Supplementary Material, Fig. S2) survived
leave-one-out analyses (Supplementary Material, Table S5), as
the removal of any individual SNP from the analysis had little
effect on observed effect estimates. These results provide
evidence to support a causal role for circulating IL-18 levels in the
pathogenesis of IBD and eczema/dermatitis. Moreover, reverse
MR (Supplementary Material, Table S6) and theMRdirectionality
test (26) (Supplementary Material, Table S7) showed that reverse
causation was unlikely for any of the associations identified in
either the conservative or liberal MR analysis.
Moloc uncovers immune cell-specific drivers of IMD
For cytokines and IMDs where evidence of a causal association
was detected using MR,we applied themolocmethod (24) to test
whether gene expression for the gene encoding the cytokine, the
cytokine protein itself and associated IMD trait all shared the
same causal variant. Supplementary Material, Fig. S1B provides
an overview of this analysis. At each loci assessed, expres-
sion quantitative trait loci (eQTL), protein quantitative trait loci
(pQTL) and GWAS effect estimates were used by moloc to assess
whether they shared a common causal variant. Furthermore,
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Figure 1. Conservative MR analysis detects associations between circulating inflammatory biomarkers and IMDs. Volcano plot of conservative MR analysis illustrating
associations between inflammatory cytokines and complex traits. Red (upper) line represents Bonferroni corrected threshold (P ≤6.17×10−4) and black dotted line
(bottom) represents unadjusted threshold (P ≤0.05).
the moloc analysis was performed 3 times for each association,
using eQTL from the BLUEPRINT project derived from either
human CD14+ CD16− monocytes, CD16+ CD66b+ neutrophils or
CD4+ CD45RA+ T cells (25).
Figure 2. Liberal MR identifies a putative causal relationship between circulating
levels of IL-18 and IBD that survives leave-one-out sensitivity analysis. Leave-
one-out MR analysis for SNPs used as instruments for liberal MR analysis (black).
Results show that this effect is not likely to be due to an individual SNP when
compared to the observed effect of all SNPs (red). All SNPs in the leave one out
analysis are trans-acting.
We identified evidence of moloc between 10 combinations
of immune cell eQTL, IMD-associated loci and inflammatory
biomarker pQTL based on a posterior probability of association
(PPA) ≥80% (Supplementary Material, Tables S8 and S9). SNPs
from each dataset used in the analysis with the strongest P-
values were reported where evidence of colocalization was
detected (Supplementary Material, Table S10). Results indicated
that IL-18 plays a role in IBD risk due to changes in gene
expression within monocytes (PPAabc =88.12%) and neutrophils
(PPAabc =96.57%), but not T cells (PPAabc =1.59%) (Fig. 3A).
Additionally, we found evidence of a T cell-specific role in
the disease pathways of eczema/dermatitis (PPAabc =91.15%)
driven by soluble IL-6R (Fig. 3B). Likewise, evidence of moloc was
identified between IL-2Rα and MS using T cell-derived eQTL
data (PPAabc =88.26%), although this gene was not expressed
in monocytes or neutrophils based on findings from the
BLUEPRINT study.
We also repeated analyses except using tissue-specific
eQTL data derived from the GTEx consortium (27). The
association between IL-18 and IBD was relatively ubiquitous, as
evidence of colocalization was observed within seven diverse
tissue types (Supplementary Material, Table S11), including
thyroid tissue (Supplementary Material, Fig. S3a). Evidence
of colocalization for the association between soluble IL-6R
and eczema/dermatitis was observed in three tissue types,
most strongly in whole blood (PPA=99.52%), which may
help shed light on the pleiotropic effects observed at this
locus (Supplementary Material, Fig. S3b). Lastly, the association
between IL-2rα and MS colocalized in two tissue types: subcu-
taneous adipose and spleen (Supplementary Material, Fig. S3c).
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Figure 3. Moloc reveals immune cell-specific divers of IMDs using immune cell eQTL data, inflammatory cytokine or cytokine receptor pQTL data and IMD GWAS data.
These plots illustrate observed effects of genetic variants at the IL-18 (A) and IL-6R (B) loci on IBD and eczema/dermatitis (E/D), respectively. Effect estimates on the
expression of IL-18 and IL6R are overlaid in each plot using eQTL data derived frommonocytes (top, a1), neutrophils (middle, a2) and T cells (bottom, a3). For simplicity,
circulating cytokine effects are not displayed within the plots but were used to calculate PPAabx scores. PPAabc values reflect the likelihood that a causal variant
influences the target cytokine (b), associated complex trait (c) and the expression of the corresponding gene (a). PPAabc ≥ 0.8 indicates evidence of colocalization (i.e.
a shared genetic variant between all three signals) and suggests that the cytokine (or its receptor) is a putative driver of the IMD when it is expressed within the cell
type of interest.
However, other tissue-specific relationships may be masked by
the lack of statistical power in current tissue eQTL datasets. As
increasing sample sizes of tissue-specific eQTL data emerge, this
method could be utilized to test the relationships within a larger
number of tissue types.
Discussion
The ways in which hundreds of functionally diverse cytokines
interact and orchestrate inflammatory responses in the
pathogenesis of IMDs are unclear (28). In this study, we
developed a framework that integrates MR with moloc to
gain insights into the molecular basis of IMD pathogenesis.
Using this framework, we found evidence to support causal
relationships between levels of circulating IL-18 and IBD, as well
as eczema/dermatitis, circulating soluble IL-6R and eczema/
dermatitis and circulating IL-2Rα and MS, amongst others
(Supplementary Material, Tables S3–4, S6–8). Additionally, we
provided evidence to suggest that these associations are likely
to be driven in an immune cell-specific manner and explored
the potential of this method to pinpoint tissue-specific drivers
of IMDs.
A T cell-mediated role for IL-2/IL-2Ra in MS has already
been well established through epidemiological and lab-based
studies (10,29). The IL-2R-targetting drug daclizumab was given
FDA (food and drug administration) approval in the United
States for the treatment of MS, but was recently withdrawn
due to serious side effects (30–32). Additionally, a causal role
for IL-18R in atopic dermatitis has recently been described,
by integrating MR and pQTL data (33). Our results provide
additional evidence to support these existing findings, as
well as identifying monocytes and neutrophils as potential
drivers of the relationship between IL-18 and eczema/dermatitis
(Supplementary Material, Table S8). However, the associations
between soluble IL-6R variation and eczema/dermatitis or IL-18
and IBD within human populations are less well understood.
Our analyses not only help establish evidence for causal
relationships between these inflammatory biomarkers and
IMDs but also help characterize their cell type-specific nature.
IL-18, a member of the IL-1 superfamily of cytokines, is
a potent inducer of Th1-mediated inflammation and IFN-γ
production (34). This cytokine was first linked to IBD nearly
20 years ago, where it was shown to be highly expressed
in intestinal tissues derived from IBD patients, compared to
healthy control patients (35). Using murine IBD models, deletion
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz155/5528728 by U
niversity Library user on 12 Septem
ber 2019
Human Molecular Genetics, 2019, Vol. 00, No. 00 5
of il-18 or its receptor il-18r1 has been shown to be protective
against inducible colitis, by controlling goblet cell function
and maintaining intestinal barrier homeostasis (36). Despite
strong evidence to suggest a role for IL-18 in IBD in mice,
whether there was a causative role within human populations
remained unclear. Our study provides evidence that IL-18 is
likely the causal gene responsible for the association with
IBD at this locus, as well as out MR analysis supporting a
causal role for IL-18 in the disease pathogenesis of IBD within
human populations. Furthermore, themoloc analyses suggested
that innate immune cells such as monocytes and neutrophils
are likely to drive this association, supporting the current
dogma that innate production of IL-18 stimulates Th1/Th17-
mediated autoimmunity in IBD (37). The T cell-specific eQTL
data currently available for moloc analyses concerned naïve
CD4+ T cells (38). More eQTL data concerning activated and
differentiated immune cell subsets, such as macrophages,
dendritic cells and T helper cell subsets (i.e. Th1, Th2, Th17,
Treg), are required for additional immune cell subset-specific
moloc analysis, to further elucidate the molecular pathways
which drive IMDs. Interestingly, small molecule inhibitors that
target and repress IL-18-mediated signalling events are currently
under development, although not for the treatment of IBD (39).
A recently published phase II trial of an IL-18 binding protein (IL-
18 bp) drug to treat adult-onset Still’s disease demonstrated a
favourable efficacy safety profile (40). If further trails are deemed
successful, IL-18 bp drugs may also be used to target other IMDs
such as IBD.
IL-6R is the receptor of the pro-inflammatory cytokine IL-6,
which can exist in a membrane-bound state on the surface of
leukocytes and hepatocytes (classical) or in soluble form (trans)
(41). Both classical and trans IL-6R signalling culminates in the
expression of signal transducer and activator of transcription
3, which promotes inflammation via the expression of genes
encoding antiapoptotic proteins and cytokines (42). However,
classical IL-6 signalling can act on few cell types compared to
trans IL-6 signalling, which can act on any cell that has the
cell-bound signal transducer, gp130 (43). One GWAS previously
reported an association between elevated soluble IL-6R levels
resulting from an SNP in IL-6R and atopic dermatitis (44).We pro-
vide evidence from the conservativeMR andmoloc analyses that
supports a causal role between soluble IL-6R and eczema/der-
matitis. The ratio of classical to trans IL-6R fluctuates as a result
of levels cell-bound gp130, receptor shedding by cells expressing
membrane-bound IL-6R and changes to the amount of receptor
being synthesized by cells (43). Therefore, analyses combining
instruments that affect the classical or trans-signalling pathways
would provide a clearer insight into the role of IL-6 signalling
in disease. Interestingly, activated CD4+ T cells have been
shown to increase levels of soluble IL-6R via IL-6R shedding;
this mechanism is thought to have a role in the development of
autoimmune diseases,which are oftenmediated by autoreactive
T cells (45,46). Through the moloc analysis, we showed that
eczema/dermatitis was likely to be driven by IL-6R expression in
T cells (Fig. 3B; Supplementary Material, Table S8). This finding
is supported by evidence of increased IL-6R shedding leading
to an increase in soluble IL-6R in people diagnosed with atopic
dermatitis compared to healthy controls (44).
Relatively few SNPs have been associatedwith changes in the
circulating inflammatory biomarkers investigated in this study,
as most of the GWAS summary statistics used to identify our
instruments were derived from cohorts with fewer than 9000
people (18,19,23); this is likely due to the high cost of quantifica-
tion of circulating cytokines and cytokine receptors from blood.
Our reverse MR analysis may therefore have been underpowered
to evaluate evidence of reverse causation, although supplement-
ing this analysis using the Steiger directionality test also sug-
gested that this was unlikely for the associations we identified.
As sample sizes for GWAS of circulating cytokines increase, the
analysis pipeline illustrated by this studywill have further power
to detect novel relationships between markers of inflammation
and complex disease. Moreover, our moloc analysis assumes
only one causal variant is responsible for associations. While
current sample sizes of molecular traits can typically only be
instrumented using a single independent cis-QTL, future studies
uncovering multiple independent QTL on a large scale should
benefit from alternative approaches to genetic colocalization.
Furthermore, applying MR analyses as proposed in our study in
a phenome-wide manner can help elucidate potential adverse
side effects of therapeutic intervention (47).
In conclusion,wehave found strong evidence supporting new
and known causal, immune cell-driven relationships between
inflammatory biomarkers and IMDs. Triangulation of results
from these analyses, with published results from experimental
models of IMDs and GWAS, suggests that targeting IL-18 or its
receptor, IL-18R, may be promising for the treatment of IBD. We
believe our analysis framework could be applied by other studies
with alternative hypotheses, as a way of disentangling complex
biochemical cell signalling pathways and identifying molecules
and cell types that are likely to drive disease for drug target
prioritization.
Materials and Methods
Data sources
For our two-sample MR analysis, we harnessed genetic instru-
ment data for 10 circulating inflammatory cytokines or solu-
ble cytokine receptors (Supplementary Material, Table S1) from
summary statistics of previously published GWAS (18,19,23,48).
The SNP used as an instrument for IL-6R affected levels of soluble
IL-6R. The SNPs chosen in this analysis have been shown to
be robustly associated with a change in circulating levels of a
cytokine (P <5×10−8) and are in cis with the gene of interest
(i.e. the SNP was located within a 1 MB distance of the gene that
encoded the cytokine or cytokine receptor of interest). Data con-
cerning IMD outcomes (Supplementary Material, Table S2) were
derived from large-scale GWAS using the MR-Base platform (49).
For the moloc analysis, we harnessed human monocyte (CD14+
CD16−), neutrophil (CD16+ CD66b+) and T cell (CD4+ CD45RA+)
eQTL data from the BLUEPRINT epigenome project (38). All data
used were derived from populations of European descent.
Mendelian randomization
MR follows three assumptions: (1) that the selected instruments
used are robustly associated with the exposure, (2) that the
selected instruments are unconfounded and (3) that the selected
instruments can only influence the outcome via the exposure.
Using randomly inherited unmodifiable SNPs associated with
circulating inflammatory cytokine levels through GWAS as
genetic instruments for MR satisfies assumptions 1 and 2. We
performed two-sample MR with the MR-Base platform (49),
using two different analysis methods (Supplementary Material,
Fig. S1A) as described below, depending upon available data.
Conservative two-sample MR was used to analyze the causal
effect of cytokines using SNPs at target genes encoding the
inflammatory biomarkers of interest. As such, for this analysis
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we used a single SNP acting in cis as a genetic instrument (i.e.
located within a 1 MB distance of the target gene encoding the
cytokine with P <5×10−08). As only one genetic instrument was
used in this analysis, effect estimates were based on the Wald
ratio test (50). For single genetic variant j, this can be calculated
by taking the ratio of the gene–outcome association (denoted by
ˆj) and the gene–exposure association (denoted γˆ j) estimates
βˆj = ˆj
γˆ j
.
Where possible, liberal MR was also used to analyze the causal
effect of circulating inflammatory biomarkers on IMDs. In con-
trast to the conservative MR analysis, liberal MR used multiple
SNPs as genetic instruments that were either acting in cis or
trans (i.e. over 1 MB distance from the target gene encoding the
cytokine with P <5× 10−08).
To identify instruments for the liberal MR we undertook
genome-wide LD clumping based on P <5× 10−08 and r2 <0.001.
A leave-one-out MR analysis was performed in parallel with
liberal MR to ensure that causal effects were not observed due to
the influence of a single SNP.As two ormore genetic instruments
were available for liberal MR, we used the inverse variance
weighted method to obtain MR effect estimates (50).
βˆIVW =
∑
j γˆ
2
j σ
−2
Yj βˆj
∑
j γˆ
2
j σ
−2
Yj
,
where σYj is the standard error of the gene-outcome estimate for
variant j.
For both conservative and liberal MR analyses, we used the
Bonferroni correction to calculate an adjusted P-value threshold
(conservative: P ≤6.17× 10−4, liberal: P ≤6.94×10−4) to account
for multiple testing, where
Threshold = 0.05
No.Exposures X No.Outcomes
.
We subsequently undertook reverse MR analyses for all asso-
ciations that survived multiple testing to investigate reverse
causation (i.e. the likelihood that genetic predisposition to dis-
ease has an influence on inflammatory cytokine levels). As an
additional sensitivity analysis, we used the MR Steiger direc-
tionality test to assess the directionality of associations between
inflammatory cytokines and complex traits (26).
Multiple-trait colocalization analysis
We applied the moloc approach (24) to immune cell-specific
eQTL data, inflammatory biomarker pQTL data and IMD-
associated loci data to identify putative immune cell-specific
drivers of IMDs (Supplementary Material, Fig. S1B). The moloc
method uses a Bayesian statistical framework to calculate PPA
scores to measure the degree of colocalization between gene
loci using three or more datasets. PPA scores of ≥80% are likely
to share a common genetic causal variant based on evaluations
undertaken by the authors (24). We obtained eQTL data derived
from concerning neutrophils (CD16+ CD66b+), monocytes
(CD14+ CD16−) and T cells (CD4+ CD45RA+) (38). We ran
independent analyses for each of the three immune cell types,
testing the degree of colocalization between immune cell eQTL,
with inflammatory biomarker pQTL and IMD-associated loci.
We chose to perform moloc for inflammatory biomarkers
and IMDs in this instance based upon a P-value threshold <0.05
in either the conservative or liberal MR analysis. Along with
investigating cell-type specificity for identified associations, this
analysis was used to detect evidence of a coordinated system
that is consistentwith causality (i.e. gene expression and respec-
tive protein products colocalize with the associated complex
traits). As such these findings can complement evidence from
MR to detect putative causal effects between biomarkers and
disease.
Finally, we undertook exploratory moloc analyses to inves-
tigate gene expression within different tissue types using data
from the GTEx consortium v6p (51). Our three traits in each
analysis were the circulating inflammatory cytokine using pQTL
data, the complex trait with strongest evidence of association
with the cytokine in either the liberal or conservative MR anal-
yses and tissue-specific gene expression for the cytokine using
GTEx eQTL data. We only investigated tissue types with at least
one eQTL (P <1.0×10−04) for the target cytokine gene due to the
small sample sizes concerning tissue-specific eQTL in the GTEx
database. As in the immune cell eQTL moloc analysis, evidence
of colocalization was based on a PPA score of ≥80%.
All statistical and bioinformatics analyses were undertaken
using R statistical software version 3.31 (52). Plots illustrating
multiple trait colocalization were generated using base R graph-
ics, whereas our volcano plot was generated using ggplot (53).
Supplementary Material
Supplementary Material is available at HMG online.
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